Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login


Product update

Natecal D3 interactions update

The summary of product characteristics of Natecal D3 (calcium carbonate and cholecalciferol; Chiesi) 600mg + 400 I.U. chewable tablets now warns that the calcium and alkali intake from other sources (food, dietary supplements and other drugs) should be taken into consideration when prescribing calcium supplements. If very high doses of calcium are taken concomitantly with absorbable alkali agents (like carbonate), this could lead to milk-alkali syndrome. In addition, it states that rifampicin may reduce the activity of vitamin D3, since it increases the rate of its metabolism.

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2015.20068955

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.